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Schizophrenia and bipolar disorder are leading causes of morbidity across all populations, with heritability estimates of ~80% indicating
a substantial genetic component. Population genetics and genome-wide association studies suggest an overlap of genetic risk factors
between these illnesses but it is unclear how this genetic component is divided between common gene polymorphisms, rare genomic
copy number variants, and rare gene sequence mutations. We report evidence that the lipid transporter gene ABCA13 is a susceptibility
factor for both schizophrenia and bipolar disorder. After the initial discovery of its disruption by a chromosome abnormality in a person
with schizophrenia, we resequencedABCA13 exons in 100 cases with schizophrenia and 100 controls. Multiple rare coding variants were
identiﬁed including one nonsense and nine missense mutations and compound heterozygosity/homozygosity in six cases. Variants
were genotyped in additional schizophrenia, bipolar, depression (n > 1600), and control (n > 950) cohorts and the frequency of all
rare variants combined was greater than controls in schizophrenia (OR ¼ 1.93, p ¼ 0.0057) and bipolar disorder (OR ¼ 2.71, p ¼
0.00007). The population attributable risk of these mutations was 2.2% for schizophrenia and 4.0% for bipolar disorder. In a study of
21 families of mutation carriers, we genotyped affected and unaffected relatives and found signiﬁcant linkage (LOD ¼ 4.3) of rare vari-
ants with a phenotype including schizophrenia, bipolar disorder, and major depression. These data identify a candidate gene, highlight
the genetic overlap between schizophrenia, bipolar disorder, and depression, and suggest that rare coding variantsmay contribute signif-
icantly to risk of these disorders.Introduction
The lifetime prevalence of both schizophrenia (MIM
#181500) and bipolar disorder (MIM %125480) is about
1% and of major depressive disorder (MIM #608516)
around 15%.1,2 With onset in young adulthood and life-
long duration, these illnesses impose a massive burden
on individuals, their families, and healthcare providers.3
Although current symptom-based classiﬁcations deﬁne
these as separate mental disorders, the boundaries between
diagnoses are indistinct. Thus the incidence of depression
and bipolar disorder is increased among relatives of
probands with schizophrenia,2,4 and twin studies conﬁrm
genetic and environmental correlations between bipolar
disorder and major depression.5 Estimated heritabilities
of more than 80% for schizophrenia and bipolar
disorder6,7 and 40% for recurrent major depression8 haveThe Americandriven the search for causative genes. Various approaches
including linkage, gene association studies, investigation
of cytogenetic abnormalities, and, recently, the detection
of copy number variants (CNVs) have contributed to our
understanding of genetic risk in these conditions but
have, necessarily, only interrogated particular aspects of
the continuum of human genetic variation. Recent
genome-wide association studies (GWAS) that probe
common variation at the whole genome scale in large
case-control cohorts have found, and sometimes repli-
cated, signiﬁcant associations of a number of candidate
genes with schizophrenia and bipolar disorder and have
found substantial overlap of risk factors between these
two illnesses.9–14 These studies have led to a reevaluation
of models of the inheritance of schizophrenia and suggest
that common polygenic variation may explain more than
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However, rare CNVs involving genes also make an impor-
tant additional contribution to the total genetic variation
associated with disease, and a parallel role for rare coding
sequence variants seems likely.15–17 In particular, the role
of rare mutations of large effect (genotype relative risk > 2)
remains largely unexplored and is unlikely to be clariﬁed
by association strategies via common SNPs.
In the same way that CNVs have proved informative, the
study of rare cytogenetic abnormalities can reveal major
gene effects on disease risk for the individual and provide
useful insights into etiological pathways relevant to illness
in the wider population. The genes DISC1, PDE4B, GRIK4,
and NPAS3 have each been identiﬁed at unique transloca-
tion breakpoints in single patients with schizophrenia and
subsequently found to be associated with both schizo-
phrenia and bipolar disorder in populations.18–25
In this paper we describe the discovery, through cytoge-
netics, of a candidate gene, ABCA13, for schizophrenia,
bipolar disorder, and depression. ABCA13 is a member of
the adenosine triphosphate (ATP)-binding cassette (ABC)
super-family encoding transporters shuttling a variety of
substrate/allocrites across cellular membranes.26 Gene
mutations in members of the seven ABC subfamilies (A-G)
contribute to human disorders withMendelian or complex
inheritance.27 In higher organisms, ABC proteins typically
contain two transmembrane domains (TMDs) and two
cytoplasmic nucleotide binding domains (NBDs), the latter
containing characteristic ATP-binding Walker A and B
motifs. We resequenced ABCA13 gene exons encoding
these key functional domains in a ‘‘discovery’’ cohort of
100 cases with schizophrenia and 100 controls and identi-
ﬁed 10 nonsynonymous rare coding variants. The
frequency of these variants was then determined in a
‘‘test’’ sample of subjects with schizophrenia, bipolar
disorder, major depression, and controls. Structural
modeling and in silico prediction tools suggested patho-
logical effects. We followed up affected and unaffected
relatives of probands with mutations and demonstrated
signiﬁcant linkage of mutations with a phenotype that
included schizophrenia, bipolar disorder, and depression.
Finally, we determined that ABCA13 protein is expressed
in mouse and human hippocampus and cortex, both
regions relevant to schizophrenia and bipolar disorder.
Material and Methods
Clinical Description of the Individual Carrying
the Complex Chromosomal Rearrangement
inv(7)(p12.3;q21.11), t(7;8)(p12.3;p23)
The 48-year-old male carrying the complex chromosomal rear-
rangement inv(7)(p12.3;q21.11), t(7;8)(p12.3;p23) was identiﬁed
by W.J.M. and was initially described in the hospital case notes as
carrying a simple t(7;8) reciprocal translocation. The patient gave
full consent to the study andwas interviewedon separate occasions
by a consultant psychiatrist (W.J.M.) and a psychiatric nurse.
The patient had a diagnosis of severe chronic schizophrenia,
with continuous symptoms since his ﬁrst admission to psychiatric834 The American Journal of Human Genetics 85, 833–846, Decemhospital at the age of 16. From his records and discussions with
ward staff, there was clear evidence of auditory hallucinations
and bizarre delusions of a persecutory and grandiose nature in
the past lasting more than 6months. After an initial series of inpa-
tient stays, he had been continuously in hospital for more than
25 years. On review he showed the classical negative signs of
severe chronic schizophrenia with self-neglect to the extent that
he needed complete support with self-care, and he showed formal
thought disorder and exhibited motor stereotypies with restless-
ness and frequent pacing. All these symptoms had been con-
stantly present for many years. He received clozapine and haloper-
idol as treatments for his schizophrenia and procycline to
counteract side effects of these. He was on no other medications
save amild laxative. There had been no contact with anymembers
of his family and details of family history were not available.
Clinical Description of Patient and Control Cohorts
The study was approved by the Central Ofﬁce of Research Ethics
Committees (COREC) in Scotland and all subjects gave informed
written consent. Subjects were from the Northeast and Southeast
of Scotland contacted through in-/out-patient services of hospitals
in Scotland, and diagnoses were made according to DSM-IV
criteria.28 All patients were interviewed by an experienced psychi-
atrist or psychiatric nurse via the ‘‘Schedule for Affective Disorders
and Schizophrenia-Lifetime’’ version (SADS-L),29 supplemented
by hospital case note review and information from carers and
relatives. Diagnosis was reached by consensus between two
psychiatrists.
A family study was designed to: (1) determine whether the rare
variants were de novo or familial mutations; (2) describe the range
of phenotypes in individuals with variants; and (3) test for linkage
between variants and different phenotypes. Attempts were made
to contact all ﬁrst and second degree relatives of the probands
who carried one of the ten variants selected for follow up. Some
probands were members of large families previously recruited for
linkage studies, and when possible these families were revisited
so that diagnoses could be conﬁrmed or updated. DNA samples
were obtained from 106 relatives of 21 individuals carrying one
of the rare mutations. DSM-IV diagnoses of family members
were based on direct interview by a psychiatrist as described above.
Controls of similar North European ancestry were recruited
through: (1) the South of Scotland Blood Transfusion Service
and the Grampian Blood Transfusion service, (2) students taking
part in an unrelated study, (3) hospital staff and social networks
of the research team, and (4) the 1936 Lothian Birth Cohort
(LBC1936).30 Controls were not screened for personal or family
history of psychiatric illness.
These case-control individuals are part of a stable population
that shows little evidence of stratiﬁcation.11 Moreover, this cohort
has been extensively genotyped in case-control studies of candi-
date genes producing both negative and positive results, suggest-
ing a lack of cohort-dependent frequency bias.
Fluorescence In Situ Hybridization Analysis
BAC and fosmid clones mapping to 8p23.3 and 7p12.3 were
selected with the UCSC genome browser database (Table S1 avail-
able online). Clone DNA prepared with the QIAGEN miniprep kit
was labeled with Biotin dUTP or Digoxigenin dTTP by nick trans-
lation and hybridized to patient metaphase spreads with standard
FISH methods.22 Slides counterstained with DAPI in Vectashield
antifade solution were assessed on a Zeiss Axioskop2 ﬂuorescenceber 11, 2009
microscope with a chroma number 81000 multispectral ﬁlter and
a Hamamatsu Photonics Orca-ER digital camera with SmartCap-
ture2 software (Digital Scientiﬁc, UK).
DNA Resequencing
ABCA13 is a very large gene with 62 exons, so sequencing was
restricted to selected exons encoding key functional domains:
two NBDs, two TMDs, and a conserved hydrophobic membrane-
dipping region (HDR). Oligonucleotide primers were designed
with PRIMER3 software against exons 32–35, 37–40, 43, 50–53,
and 54–59 of ABCA13 (NM_152701). PhredPhrap and Consed
software were used for resequencing analysis. Conﬁrmation of
variants was obtained through independent resequencing reac-
tions, restriction enzyme digests, cloning PCR products, and ABI
TaqMan assays (all primers listed in Table S2).
Bioinformatics: Splicing, Sequence Alignment,
Homology Modeling
Potential splice site variants were assessedwith BerkeleyDrosophila
Genome Project splice site predication tool.31 Human ABCA13
orthologs were determined with a BLAST search against the trans-
lated nonredundant sequence database (tblastn), via the NCBI
website with default parameters.32,33 Seven orthologous sequences
were retrieved (GenBank identiﬁers): Homo sapiens (259013576),
Pan troglodytes (114613334), Macaca mulatta (109066580), Mus
musculus (30023642), Rattus norvegicus (158187532), Canis famili-
aris (73981662), Bos taurus (194666167), and Gallus gallus
(50736039).
Sequences for all NBDs from ABCA transporters were retrieved
directly from the SwissProt database.34 Because of their highly
conservative sequences, the ortholog and ABCA-NBD multi-
ple sequence alignments were generated automatically with
ClustalX35 (Figure S1).
Numerous examples of experimentally determined ABC nucleo-
tide-binding domains are deposited in the Protein Data Bank
(PDB).36 For modeling human ABCA13-NBD1 (SwissProt Acces-
sion No: Q86UQ4; amino acid residues 3842–4074), three of its
closest experimentally determined homologs, ascertained by a
BLAST search against the PDB, were used as templates. These
included X-ray structures from Thermatoga maritima (PDB ID:
1VPL; 2.1 A˚) (Joint Center for Structural Genomics, unpublished),
CysA from Alicyclobacillus acidocaldarius (PDB ID: 1Z47, chain A;
1.9 A˚), and MalK from Escherichia coli (PDB IDs: 1Q12, chain
A).37 The higher resolution 1Q12 (2.6 A˚) structure of MalK E. coli
was selected instead of 1Q1E (2.9 A˚) and 1Q1B (2.8 A˚). The target
ABCA13-NBD1 shares 31%, 29%, and 30% sequence identity,
respectively (~52%–54% similarity), when compared with the
templates from N-to-C terminus.
The alignment between the target and template sequences for
modeling purposes was based on an initial multiple sequence
alignment among them and a range of other-related protein
sequences with the program MUMMALS38 (Figures S2 and S3).
Related sequences were ﬁrst identiﬁed via the Network Protein
Sequence Analysis server, with a BLASTsearch against the Swis-
sProt database.34,39 After removing identical sequences from the
returned output and considering only those sequences with at
least 200 amino acids in length, 413 protein sequences were iden-
tiﬁed, and their corresponding homologous NBD-like protein
regions were extracted (E-value cut-off % 1e-10) and aligned
with MUMMALS (Hidden Markov model option: HMM_1_3_1;
Identity threshold: 0.6). The target-template alignment wasThe Americafurther manually reﬁned from the multiple sequence alignment
in order to place gaps optimally guided by positioning of
secondary structure elements, identiﬁed by STRIDE for the
templates, and predicted by PsiPred version 2.5 for the target
sequence.40–42
The program Modeler release 8 version 2 was used for model
building based upon the aforementioned alignment.43 Twenty
models were generated, and the one with the lowest objective
function score was selected as the representative model. Noniden-
tical side chain residues (between target and templates) for the
representative model were optimized with the side chain replace-
ment program, SCWRL version 3.44,45 The model was then
protonated under SYBYL version 6.9 (Tripos Associates, St. Louis,
MO) and subject to brief energy minimization (30 steps steepest
descent followed by 30 steps conjugate gradients) employing
the Tripos forceﬁeld to remove clashes and bad geometries.46
The model was ﬁnally checked for valid stereochemistry with
PROCHECK version 3.5.4 (most favored regions, 89.8%; addi-
tional allowed regions, 9.8%; generously allowed regions, 0%;
disallowed regions, 0.5%) and validated with the MetaMQAP II
server47 (GDT_TS, 69; RMSD, 3.3 A˚).47 All surface area calculations
were performed with GETAREA version 1.1 via the following
parameters: radius of water probe in Angstroms ¼ 1.4; output
level ¼ Area per residue.48 The hydrogen-bonding network was
analyzed with SYBYL version 6.9 (Tripos Associates) and the
Protein Interactions Calculator.49
Statistical Analysis
Variants for further study were selected from resequencing
‘‘discovery’’ set data. However, all statistics relating to individual
and global variant inﬂuence were based solely on TaqMan geno-
typing data derived from the secondary ‘‘test stage.’’ This approach
ensured unbiased estimates of effect sizes. For each variant in the
test stage, allele frequencies were compared with Fisher’s exact
test. A combined association test across all nonsynonymousmuta-
tions was performed by comparing the number of variants in cases
to the number in controls. To account for variable sample size
across the total, sample size was adjusted to N ¼ n / (S(1/Ni)),
where Ni is the samples size at the ith variant and n is the number
of variants. The number of observed variants was adjusted as
S(pi)*N, where pi is the frequency of the ith variant. The popula-
tion attributable risk (PAR) was calculated as follows: PAR(%) ¼
100 * P(any ns variant) * (OR  1) / [1 þ P(any ns variant) *
(OR  1)] with P(any ns variant) ¼ the probability of having any
of the ns variants, calculated from the controls. This probability
(¼ 0.024) is the same for all groups because it is calculated from
the controls.
Nonparametric linkage analysis was conducted with Merlin50 to
calculate allele sharing between all sets of affected relatives in the
14 families informative for linkage with two or more affected rela-
tives, under both a ‘‘narrow’’ phenotype deﬁnition (schizophrenia
and bipolar disorder) and a ‘‘broad’’ phenotype (schizophrenia,
bipolar disorder, and major depression). For each SNP, the allele
frequency on which identity-by-descent is estimated was speciﬁed
to be 0.0025 (average mutation rate in controls). The LOD score
and p value were calculated via the exponential model described
by Kong and Cox.51
Immunoﬂuorescence
Two separate Abca13 antibodies, NC1 and 807, were raised in
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brain sections (10 mm thickness) were ﬁxed in ice-cold acetone and
blocked, incubated with primary antibody, and washed in phos-
phate-buffered saline þ 0.1% Tween. After Alexa Fluor ﬂuorescent
donkey anti-rabbit secondary antibodies incubation and washing,
slides were mounted in DAPI/antifade solution. Images were
captured as described for FISH.
Results
Cytogenetics
We characterized a chromosomal rearrangement,
inv(7)(p12.3;q21.11), t(7;8)(p12.3;p23), comprising a peri-
centric inversion of chromosome 7 coupled with a translo-
cation between chromosomes 7 and 8 in a patient with
chronic schizophrenia. FISH conﬁrmed only one break-
point, at 7p12.3, directly disrupted a gene, ABCA13
(Figures 1A and 1B; Table S1). We hypothesize that
ABCA13 disruption causes illness in this individual
through haploinsufﬁciency that commonly occurs in simi-
larly truncated transcripts through nonsense-mediated
decay.
Resequencing Functional Domain Exons
The ABCA13 locus had not previously been associated
with psychiatric disorders. To investigate whether rare
functional variants in this gene contribute to psychiatric
disorders, we resequenced 19 out of the total of 62 exons
in the discovery cohort of 100 unrelated cases with schizo-
phrenia (the same diagnosis as the patient with the chro-
Figure 1. Cytogenetic Disruption of the
ABCA13 Gene and Location of Functional
Domain-Encoding Exons Selected for Rese-
quencing
(A) A pericentric inversion of chromosome 7 and
reciprocal translocation with chromosome 8
identiﬁed in a patient with schizophrenia. The
location of the disrupted ABCA13 gene is indi-
cated on the short arm of chromosome 7.
(B) Fluorescence in situ hybridization image
showing patient metaphase chromosomes hy-
bridized with breakpoint fosmid G248P8188G7.
Three hybridization signals are located on
normal chromosome 7 and derived chromo-
somes 7 and 8.
(C) Schematic of theABCA13 locus. The positions
of gene exons and the fosmid probes positioning
the breakpoint (red box) are indicated. The rela-
tionship between resequenced exons and
ABCA13 protein functional domains is high-
lighted together with the approximate positions
of the ten rare variants studied in greater detail.
mosome abnormality) and 100 controls.
These exons were selected to encode key
functional domains: two NBDs, two TMDs,
and a conserved hydrophobic membrane-
dipping region (HDR) (Figure 1C).
We identiﬁed 32 variants not previously
recorded in dbSNP: 20 in exons and 12
within ﬂanking intronic sequences (Table 1; Figure S4).
Of the 20 exonic variants, 14 were nonsynonymous, of
which 8 were identiﬁed initially in schizophrenia cases, 3
in schizophrenia and controls, and 3 in controls only.
The Frequency of Variants in Cases and Controls
Ten variants were selected for further analysis in a test
cohort of subjects with schizophrenia (1019), bipolar
disorder (680), major depression (365), and 2270 controls,
based on the criteria: (1) present in no more than one of
100 controls, (2) causing a nonconservative amino acid
change, and (3) showing cross-species conservation of
the wild-type residue (Table 2). Genotyping assays de-
signed against these 10 mutations were used to screen
cases and controls. Despite relatively small numbers, three
variants (H3609P, T4031A, and T4550A) were signiﬁcantly
more frequent in bipolars than controls and R4843L was
more common in schizophrenia (Table 2), although none
remained signiﬁcant after correction for multiple testing
of 10 variants in three phenotypes. A global comparison
of the frequencies of all ten variants between cases and
controls in this test stage showed a signiﬁcant increase in
the frequency of mutations in schizophrenia (p ¼ 0.0057
OR ¼ 1.93 95% CI 1.24) and bipolar disorder (p ¼
0.00007 OR 2.71 95% CI 1.73) but only a trend in major
depression (p¼ 0.096 OR 1.67 95%CI 0.88). Similar signif-
icance was obtained when all case diagnoses were grouped
(p ¼ 0.0004 OR ¼ 2.1 95% CI 1.45). The population attrib-
utable risks of the variants were 2.21%, 4.00%, and 2.61%836 The American Journal of Human Genetics 85, 833–846, December 11, 2009
Table 1. All ABCA13 Variants with Provisional dbSNP Identifiers Identified during the Resequencing Discovery Stage of This Study
Domain
Chr7 Location bp
NCBI Build 36.1
Base
Change
dbSNP
Reference
AA
Change Substitution Type
MAF
Cases
MAF
controls
Discovery
Populationa
TMD1 48,382,318 G/A ss136294996 R3604Q missense A: 0.0003 A: 0.0005 case
TMD1 48,382,333 A/C ss136295002 H3609P missense C: 0.0085 C: 0.0043 both
TMD1 48,382,337 A/C ss136295006 P3610P synonymous C: 0.0096 C: 0.0000 case
TMD1 48,382,337 A/T ss136295010 P3610P synonymous T: 0.0048 T: 0.0037 both
TMD1 48,382,619 T/G ss136295014 S3704R missense/splice variant G: 0.0003 G: 0.0000 case
TMD1 48,384,364 C/T ss136295018 intronic T: 0.0095 T: 0.0160 both
TMD1 48,384,474 A/G ss136295022 intronic G: 0.0045 G: 0.0000 case
TMD1 48,384,623 T/C ss136295026 intronic C: 0.0048 C: 0.0053 both
TMD1 48,398,156 G/A ss136295030 intronic A: 0.0523 nd case
TMD1 48,398,232 G/C ss136295034 intronic C: 0.0048 nd case
NBD1 48,399,292 C/G ss136295038 L3861L synonymous G: 0.0000 G: 0.0052 control
NBD1 48,399,322 T/C ss136295042 T3871T synonymous C: 0.0000 C: 0.0052 control
NBD1 48,413,738 C/T ss136295046 intronic T: 0.0092 nd case
NBD1 48,420,643 C/T ss136295050 intronic T: 0.1651 T: 0.2067 both
NBD1 48,420,683 A/G ss136295054 T4031A missense G: 0.0009 G: 0.0000 case
NBD1 48,420,731 C/G ss136295058 L4047V missense (>1% frequency) G: 0.0169 G: 0.0104 both
NBD1 48,420,834 C/G ss136295062 intronic G: 0.1651 G: 0.2067 both
HDR 48,465,394 T/C ss136295066 P4260P synonymous C: 0.0000 C: 0.0052 control
HDR 48,465,399 A/G ss136295070 H4262R missense G: 0.0003 G: 0.0000 case
TMD2 48,518,027 C/T ss136295074 R4454C missense (>1% frequency) T: 0.0142 T: 0.0156 both
TMD2 48,518,057 C/A ss136295078 L4464M missense (>1% frequency) A: 0.0095 A: 0.0208 both
TMD2 48,526,874 A/G ss136295082 T4550A missense A: 0.0056 A: 0.0014 case
TMD2 48,526,994 C/T ss136295086 R4590W missense T: 0.0044 T: 0.0019 control
TMD2 48,527,112 C/G ss136295090 intronic G: 0.0286 G: 0.0161 both
TMD2 48,530,327 C/G ss136295094 P4648A missense G: 0.0000 G: 0.0004 control
NBD2 48,534,459 A/G ss136295098 R4707R synonymous G: 0.0500 G: 0.0526 both
NBD2 48,534,520 C/T ss136295102 R4728X nonsense T: 0.0025 T: 0.001 case
NBD2 48,538,544 C/T ss136295106 intronic T: 0.0000 T: 0.0153 control
NBD2 48,538,545 C/T ss136295110 intronic T: 0.0000 T: 0.0052 control
NBD2 48,597,311 A/G ss136295114 I4841V missense G: 0.0040 G: 0.0000 case
NBD2 48,597,317 C/T ss136295118 R4843C missense T: 0.0050 T: 0.0031 control
NBD2 48,604,841 C/A ss136295122 intronic A: 0.0519 A: 0.0789 both
The genomic and functional domain location of the variants is displayed together with mutation class and frequency in the discovery set. The ten variants selected
for further genotyping are shown in bold.
a Indicates the resequencing cohort in which the variant was originally discovered.for schizophrenia, bipolar disorder, and across all diag-
noses, respectively.
Study in Families of Individuals with Mutations
Relatives of probands carrying eight of the ten rare muta-
tions gave consent to take part in the family study
designed to investigate the phenotypes associated with
mutations and to determine whether these were de novoThe Americanor familial mutations. 106 relatives in 21 families were gen-
otyped (Figure 2). Families ranged in size from 2 to 16
persons and the diagnoses in family members (including
probands) carrying one of the variants were schizophrenia
(14), bipolar disorder (10), major depression (19), minor
depression, anxiety, or alcoholism (3), and no psychiatric
diagnosis (19). No variants were conﬁrmed as de novo
mutations.Journal of Human Genetics 85, 833–846, December 11, 2009 837
Table 2.
SCZ BP MDD
Variant D
ls
p Value
Odds
Ratio p Value
Odds
Ratio p Value
Odds
Ratio
1 T
2 T 0.334 1.37 0.050 2.43 0.130 2.62
3 T
4 N 0.012 inﬁnity
5 H
6 T 0.054 3.29 0.0097 5.25 0.63 1.18
7 T 0.38 1.5 0.087 2.75 0.14 2.78
8 T
9 N 0.370 1.51 0.057 3.35 0.600 1.21
10 N 0.047 2.54 0.400 1.38 0.630 1.02
Global sign 5.70E-
03
1.93
(1.24)
7.42E-
05
2.71
(1.73)
9.66E-
02
1.67
(0.88)
Population 2.21% 4.00% 0.02%
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9The Properties of Ten Rare ABCA13 Variants Genotyped in Large Test Cohorts of Cases and Controls
Representation in
Discovery Set
Representation
in Test Set
omain Exon Genomic Position Base Change
WT Residue
Conservation
Residue
Change Type
SCZ
(n ¼
100)
Controls
(n ¼ 100)
Cases
(total)
Cases by
Diagnosis
(Total)
Contro
(Total)
MD1 33 48,382,318 G/A RH, D,
R, M,
R3604Q missense 1 0 0
(1666)
0/841 SCZ,
0/494 BP,
0/331 MDD
1
(951)
MD1 33 48,382,333 A/C RH, D,
R, M, Ch
H3609P missense 3 1 25
(1607)
10/857 SCZ,
10/488 BP,
5/262 MDD
8
(939)
MD1 33 48,382,619 T/G RH, D,
R, M, Ch
S3704R miss./splice 1 0 0
(1606)
0/851 SCZ,
0/496 BP,
0/259 MDD
0
(939)
BD1 40 48,420,683 A/G RH, D,
R, M, Ch
T4031A missense 1 0 3
(2072)
0/1019 SCZ,
3/678 BP,
0/365 MDD
0
(2262)
DR 43 48,465,399 A/G RH, R,
M, Ch
H4262R missense 1 0 0
(1717)
0/837 SCZ,
0/562 BP,
0/318 MDD
0
(980)
MD2 52 48,526,874 A/G RH, D,
R, Ch
T4550A missense 1 0 18
(1608)
9/861 SCZ,
8/482 BP,
1/265 MDD
3
(938)
MD2 52 48,526,994 C/T RH, D,
R, M, Ch
R4590W missense 0 1 17
(1846)
6/874 SCZ,
7/622 BP,
4/350 MDD
4
(971)
MD2 53 48,530,327 C/G RH, D,
R, M, Ch
P4648A missense 0 1 0
(1488)
0/869 SCZ,
0/619 BP
0
(959)
BD2 54 48,534,520 C/T RH, D,
R, M, Ch
R4728X nonsense 1 0 10
(2058)
4/1004 SCZ,
5/680 BP,
1/374 MDD
5
(2270)
BD2 57 48,597,317 C/T RH, D,
R, M, Ch
R4843C missense 0 1 19
(1770)
12/815 SCZ,
5/619 BP,
2/336 MDD
6
(1025)
iﬁcance of all variants by diagnosis (95% CI lower limit shown for odds ratios):
attributable risk by diagnosis:
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.The ANonparametric single point linkage analysis with
MERLIN50 to estimate identity by descent (IBD) between
all pairs of affected relatives in the 14 multiply affected
families informative for linkage gave a combined Z score
of 4.18 and a Kong and Cox51 LOD score of 4.38 (p¼ 3.53
106), establishing signiﬁcant linkage of ABCA13 muta-
tions with a ‘‘broad’’ phenotype that included cases with
schizophrenia, bipolar disorder, and major depression.
A LOD score of 2.1 (p ¼ 0.0009) was achieved when the
analysis was performed under the more restrictive pheno-
type deﬁnition including only cases with schizophrenia
and bipolar disorder.
Genetic Properties and Clinical Phenotypes
Associated with Individual Rare Variants
Data on each variant are presented in Table 2. Figure 3
highlights the sequence conservation and structural conse-
quences of the potential null mutations R4728X and
S3704R and missense mutation T4031A. Figure S5 shows
the location of the nine predicted pathological variants
on a topological representation of ABCA13 protein.
1. R3604Q was detected in a single discovery case with
schizophrenia and one of 951 controls. A pathological
effect was predicted by pmut and Panther online utilities
(Table S3).52–55 In the family of the schizophrenia proband
(Fam19), the mutation was present in a parent and two
siblings and all three relatives had affective disorder.
2. H3609P was detected in three subjects with schizo-
phrenia and one control in the discovery cohort and was
more frequent in bipolars than controls (p ¼ 0.05 OR
2.43) in the test cohort. A pathological effect was predicted
by pmut. Eight families were followed up and themutation
was detected in four cases of bipolar illness or depression in
Fam17, three siblings with schizophrenia in Fam11, two
cases of schizophrenia, bipolar disorder, or depressions in
each of families 12, 14, and 16, and in an unaffected parent
in families 13, 15, and 18. Three bipolar cases were
compound heterozygotes carrying both the T4550A and
H3609P mutations and one person with severe chronic
schizophrenia was homozygous for H3609P whereas all
controls carrying variants were monoallelic, reinforcing
the possibility of interactive effects of rare variants on
these phenotypes.
3. S3704R, located in an extracellular loop of the ﬁrst
TMD (Figures 3C and 3F) was found in a subject with
schizophrenia in the discovery cohort and cosegregated
with schizophrenia (one case) and depression (four cases)
in the proband’s family (Fam10). The mutation was not
detected in a further 1606 cases or in 939 controls. A path-
ological effect was predicted by pmut. In addition to its
amino acid substitution, this mutation introduces a novel
cryptic splice donor site, potentially resulting in a tran-
script with a downstream frameshift and premature stop
codon. Hence, S3704R displays the features of a rare
Mendelian, highly penetrant, deleterious mutation.
4. T4031A, a missense variant located in NBD1 (Figures
3B and 3E), was identiﬁed in three individuals with bipolarmerican Journal of Human Genetics 85, 833–846, December 11, 2009 839
Figure 2. Cosegregation of ABCA13 Variants with Illness in Families
These families were all included in the linkage analysis. Images created with CraneFoot application.83disorder in a sample of 2072 cases and was absent in 2262
controls (p¼ 0.012). A pathological effect was predicted by
Panther. As with R4728X (see below), the missense variant
occurred on a distinct haplotype (Table S4), implying that
present-day carriers of the mutation are likely to be
descended from a common European ancestor.
T4031A is strictly conserved across species and among all
human ABCA NBD1s (Figure 3E; Figure S1), and we evalu-
ated the consequence of the mutation on protein structure
and function by means of a comparative three-dimen-
sional model (Material and Methods; Figures 3G and 3H).
T4031 lies within the protein core immediately adjacent
to the functional H-loop histidine residue (H4032) and in840 The American Journal of Human Genetics 85, 833–846, Decembproximity to other functional motif residues from Walker
A (G3875) and Walker B (E4001). Substitution to Ala likely
alters H-loop conformation and, in turn, catalytic activity.
The adjacent H-loop histidine residue (H4032) is essential
for ATP hydrolysis in NBDs56,57 and the equivalent
mutation, H2128R, in NBD2 of human ABCA4 has been
implicated in Stargardt disease (MIM #248200), a lipid
deposition disorder.58
5. H4262R, located distal to the HDR, was detected in a
single personwith schizophrenia and an unaffected sibling
(Fam22) but was absent from control, bipolar disorder, and
depression cohorts. A pathological effect was predicted by
pmut and PolyPhen.er 11, 2009
Figure 3. Characterization of the
R4728X, T4031A, and S3704R Rare Vari-
ants
(A–C) Sequence of wild-type (top) and
heterozygous (bottom) alleles for variants
R4728X (A), T4031A (B), and S3704R (C).
(D–F) The wild-type residues are highly
conserved within the ABCA family of
proteins and between species orthologs
for T4031A and S3704R (E, F) but less so
for R4728X (D), which most likely reﬂects
its different mode of pathological action
(hs, Homo sapiens; mm, Mus musculus; gg,
Gallus gallus).
(G) Location of T4031 and ATP-binding
site on the 3D model of ABCA13-NBD1.
The side chains of ATP-binding motifs are
shown (Walker A, cyan; Walker B, blue;
Q-loop, light brown; H-loop, pink; D-loop,
magenta; C-loop, red) andmutated residue
T4031A (green). Secondary structure was
assigned by STRIDE and schematic repre-
sentation of the 3D model produced with
PyMol.
(H) Magniﬁed view of T4031 hydrogen
bonds indicated by dashed orange lines.
The buried side chain hydroxyl group of
T4031 forms a potential ‘‘loop-stabilizing’’
H-bond with the backbone nitrogen of
H4033 and additionally with the side
chain of the catalytic Walker B amino
acid E4001, both absent in the Ala variant.
The backbone-backbone H-bond between
T4031 and L3873 is also shown. Only
amino acid residues within a 5 A˚ sphere radius to T4031 are shown (color code: carbon atoms, green; oxygen atoms, red; nitrogen atoms,
blue; hydrogen atoms not shown for clarity). The proximity of functional residues H4032 (H-loop), G3875 (Walker A), and E4001
(Walker B) is evident.6. T4550A is a missense variant found more frequently
in bipolars than controls (p ¼ 0.0097 OR 5.52) with a
similar trend in schizophrenia (p ¼ 0.054 OR 3.29) but
not depression (p ¼ 0.63 OR 1.18). Two families were fol-
lowed up and the mutation was detected in a second
sibling with schizophrenia in one family (Fam20) and an
unaffected sibling in the other (Fam21).
7. R4590W was discovered in a control and in the test
stage was relatively frequent and found in 17 cases and
4 controls. A pathological effect was predicted by pmut
and PolyPhen. No families were available for follow-up.
8. P4648Awas discovered in a single control and was not
detected in the test samples. Controls were not screened
for current or past episodes of mental illness and family
details are not available. We consider this variant nonpa-
thological.
9. R4728X, a nonsense mutation located at the start of
NBD2 (Figures 3A and 3D), was found in four cases with
schizophrenia, ﬁve with bipolar disorder, one with depres-
sion, and ﬁve controls (not screened for personal or family
history of psychiatric illness). Four of the mutation carriers
had relatives who agreed to take part in the study. In two of
these families (Fam3 and Fam4), the mutation segregated
with bipolar disorder and depression and in two (Fam5
and Fam6) with schizophrenia and depression (Figure 2).
The mutation showed incomplete penetrance and wasThe Americanfound on a distinct haplotype background (as T4031A,
see above) (Table S4). The functional signiﬁcance of the
mutation is not known but transcripts containing
nonsense mutations are commonly degraded, resulting
in reduced gene dosage. Moreover, an equivalent muta-
tion, R1275X, within the conserved A-loop motif in the
human ABCC6 gene is pathological, causing pseudoxan-
thoma elasticum (MIM #264800).59
10. R4843C was initially discovered in a control, but in
the test stage was more frequent in cases. A pathological
effect was predicted by pmut. The comparison of schizo-
phrenia (12/815) with controls (6/1025) was signiﬁcant
(p ¼ 0.047 OR 2.54). Follow-up was possible with three
families where the mutation was present in a bipolar
parent in Fam7, an unaffected parent in Fam8, and a sibling
pair with depression Fam9. A bipolar parent of the proband
with unipolar depression in Fam9 did not have the muta-
tion but we have no diagnosis for the other parent who
has the variant.
Compound Heterozygosity
Strikingly, ﬁve cases were found to be compound heterozy-
gotes and one homozygous, whereas all controls carrying
variants were monoallelic, suggesting possible additive
effects on risk. Two of the four cases with T4031A, one
with schizophrenia and one bipolar, were compoundJournal of Human Genetics 85, 833–846, December 11, 2009 841
Figure 4. Abca13 Protein Expression in the Adult Mouse Brain
Polyclonal rabbit Abca13 antibodies NC1 (A, E) and 807 (B–D, F–K) were used to detect protein expression in frozen coronal brain
sections. The pattern of cytoplasmic expression in the dentate gyrus granule cell layer (GCL) and choroid plexus was suggestive of
both golgi body/endoplasmic reticulum localization (conﬁrmed by colocalization with calnexin endoplasmic reticulum marker) (data
not shown) and centrosomal localization (A–D, where B, C, and D are DAPI nuclear staining, Abca13 expression, and merged image,
respectively). Strong expression was observed in ventricular regions, particularly the choroid plexus (E–H) and the ciliated ependymal
cells lining the ventricular system (I–K). (F) and (I), (G) and (J), and (H) and (K) are DAPI nuclear staining, Abca13 expression, andmerged
image, respectively. Images (I), (J), and (K) also contain insets showing the Abca13-positive ependymal cell cilia face on.heterozygotes also carrying the variant T4550A. Only one
relative of the two compound heterozygotes was available
for study and this unaffected parent of the proband with
schizophrenia carried only T4031A. Two bipolar cases
were compound heterozygotes carrying both the H3609P
and R4590W mutations, one bipolar case carried H3609P
and T4550A, and one person with severe chronic schizo-
phrenia was homozygous for H3609P.
Abca13 Expression in Human and Mouse Brain
RT-PCR conﬁrmed earlier reports26,60 of ABCA13 mRNA
transcript expression in brain and indicated speciﬁc
expression in human hippocampus and cortex (data not
shown). Immunological detection of Abca13 protein by
two independently raised antibodies showed low-to-
moderate expression in most adult mouse brain regions
and higher expression in dentate gyrus granule cells and
ventricular areas including choroid plexus and ependymal
cells (Figure 4).
Discussion
We have identiﬁed a cytogenetic disruption of the ABCA13
gene and 10 rare nonsynonymous mutations of which
9 demonstrated evidence consistent with a role in the
etiology of schizophrenia and bipolar disorder. Association842 The American Journal of Human Genetics 85, 833–846, Decembof ABCA13 coding variants with schizophrenia and bipolar
disorder was signiﬁcant for all variants taken together and
for speciﬁc individual variants. The population attribut-
able risk of the 10 rare variants detected was 2.2% for
schizophrenia and 4.0% for bipolar, suggesting that this
gene may have an important role in a subgroup of patients
and an inﬂuence that crosses traditional diagnostic cate-
gories. To our knowledge, this is the ﬁrst instance where
multiple and combined coding variants in a single gene
have been associated with risk of schizophrenia and
bipolar disorder.
ABCA13 had not previously been implicated as a risk
factor in major psychiatric disorders although a suggestive
role for common ABCA13 gene variants in schizophrenia
recently emerged from the International Schizophrenia
Consortium GWAS data set where a signiﬁcance level of
p < 0.001 was reached at a single SNP within ABCA13
and a cluster of SNPs within a few kb of the gene.10
The family study included affected and unaffected rela-
tives from 21 families, and in all cases the variants were
familial with no instances of de novo mutation. Associa-
tion with major depressive disorder was not signiﬁcant in
the case-control study but this was a small and conserva-
tive group because controls were not screened for personal
or family history of psychiatric illness and the control
groups would be expected to include some individuals
with depression that has a lifetime prevalence of ~15%.er 11, 2009
However, a striking ﬁnding was that the same mutation
was associated with schizophrenia, bipolar disorder, as
well as major depression in separate families. The nonsense
mutation R4728X was detected in cases with bipolar
disorder and depression in Fam3 and Fam4 and with
schizophrenia and major depression in Fam5 and Fam6.
A similar picture was found for H3609P, which was present
in three siblings with schizophrenia in Fam11 and two
cases with bipolar disorder and two with major depression
in Fam17. The family data also demonstrated incomplete
penetrance for seven of the eight variants because these
were detected in unaffected relatives. This variable pene-
trance and range of phenotypes in families with rare
ABCA13 mutations is similar to the pattern of illnesses in
relatives carrying a translocation disrupting the gene
DISC1 who were diagnosed with schizophrenia, depres-
sion, and bipolar disorder.61
Rare variants in other members of the ABCA subfamily
also give rise to variable disease phenotypes, for example
ABCA162 (two lipid-related conditions: Tangier disease
[MIM #205400] and familial hypoalphalipoproteinaemia
[MIM #604091]) and ABCA463 (four forms of degenerative
retinal dystrophy: Stargardt disease, retinitis pigmentosa
[MIM #601718], cone rod dystrophy [MIM #604116],
and age-related macular degeneration [MIM #153800]),
and it has been suggested that precise clinical presentation
may be determined by the site of the mutation.62,64
However, in the present study both missense and null
mutations contribute to a full range of phenotypes with
no clear effect of the site or class of mutation on clinical
outcome. The discovery of ﬁve compound heterozygotes
and one homozygous mutation carrier suggests that addi-
tive and interactive combinations of mutations may
contribute to these complex phenotypes.
All ABCA proteins functionally characterized to date
shuttle lipid molecules across cell membranes.65 More
than 1000 different lipid species exist in eukaryotic cells
and in addition to being structural components of cellular
membranes, different species have key roles in vesicular
trafﬁcking, signal transduction, and transcriptional regula-
tion.66,67 Although the precise allocrite for the ABCA13
transporter has not been identiﬁed, the presence of a
conserved C-terminal motif known to be shared among
the lipid transporting group suggests that it is likely to be
lipid related.68 Abnormalities in lipid metabolism have
been strongly implicated in psychiatric illness with the
most consistent ﬁnding being depletion of essential fatty
acids in tissues of schizophrenic and bipolar patients.69–74
The oligodendrocyte lineage transcription factor 2 (OLIG2)
showed association with schizophrenia,75,76 and a growing
body of evidence based on imaging studies, microarray
analysis, and metabolic and transcriptome investigation
has implicated oligodendroglial pathophysiology and
myelin biosynthesis in psychiatric disorders.77–79 Consis-
tent with these discoveries are the ﬁndings that membrane
phospholipids and the expression of genes encoding
enzymes important in sphingolipid metabolism are signiﬁ-The Americancantly altered in postmortem brain tissue from schizo-
phrenic patients andupregulated in response to antidepres-
sant drugs.80,81 Disruption of lipid membrane structures
and lipid biosynthetic pathways has the potential to affect
many important biological processes including intracel-
lular signaling pathways and neurotransmitter function.
Rare sequence variants are known to have an important
role in the inheritance of common diseases, and different
categories of ‘‘rare variant’’ have been described. Classical
rare deleterious familial mutations typically show strong
familial aggregation, have high penetrance, and low
frequencies. A second type of variant (mostly missense
mutations), have higher frequencies of up to 2%–3% in
the case population, ORs of 2 or more, and tend to show
less familial aggregation.82 In the present study S3704R
conforms to the ﬁrst class of null private mutation with
high penetrance and low frequency whereas the missense
mutations H3609P, T4550A, and R4590W show character-
istics more typical of the second class by virtue of also
being detected in controls, having moderate ORs, and
higher observed frequencies. These data lend support to a
genetic architecture of schizophrenia, bipolar disorder,
and depression comparable to other common genetically
complex and heterogeneous diseases and provide a novel
biological pathway for investigation.
Supplemental Data
Supplemental Data include ﬁve ﬁgures and four tables and can be
found with this article online at http://www.cell.com/AJHG.
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